Forest Expects Lexapro To Gain Share In Flat Antidepressant Market
This article was originally published in The Pink Sheet Daily
Executive Summary
The company projects escitalopram total Rx share will increase from 19.7% to 21.5% in the next 12 months while the antidepressant market will be down 0.5% for the same period. Lexapro market share has seen a "modest boost" as a result of FDA's seizure of GSK's Paxil CR.
You may also be interested in...
Lexapro, Namenda Inventory Workdowns Cut Forest's Fourth Quarter Sales
Wholesale inventory levels of the antidepressant Lexapro fell from 21 days at the end of 2004 to 15 days as of March 31, Forest says. Total prescription volume of the Alzheimer's agent Namenda increased, but sales were similarly negatively impacted by inventory workdowns, the company says.
Forest Lexapro “Not Approvable” For Social Anxiety Disorder
FDA’s concerns regarded reliability of data from one of the pivotal studies, Forest says – an additional study may be necessary. Forest announced Lexapro was deemed “not approvable” for panic disorder March 1.
Antidepressant MedGuide Distribution Imminent; Unit-Of-Use Packs To Follow
The new patient Medication Guide is expected to reach pharmacies the week of March 7. The standardized MedGuides will be issued as tear-off pads for about a year until manufacturers implement unit-of-use packaging, which would allow the guide to be pre-packaged with every prescription.